How to analyze the company?LEARNWhat should you know before buying?
Get a brief AI stock analysisSaves ~ 15 minutes of your time

AV

LSE:Avacta Group
Get a brief AI stock analysisSaves ~ 15 minutes of your time

AV

Avacta Group PLCLSE Avacta Group Stock Report

Get a brief AI stock analysis
Saves ~ 15 minutes of your time

Price

Market cap $B

Exchange

XLON - London Stock Exchange

FAIR VALUE

Is AVCT undervalued compared to its fair value?

The fair value of AVCT stock is hidden GBX. Relative to the market price of 73 GBX Avacta Group PLC is hidden.

Avacta Group Plc engages in the provision of Affimer reagents for licensing into third-party research and diagnostic products, and creates new Affimer medicines for development in-house and licensing to large pharmaceuti...[More about valuation]

Avacta Group PLC Fair Value

hidden
UNLOCK
What is fair value?

Market cap:

0.34 $B

Price:

73 GBX

Fair value:

hidden

Max value:

hidden

Min value:

hidden

P/E:

hidden

EPS:

-0.043

FINANCIALS

Avacta Group PLC financial for reporting period

Income Statement

0.012 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.011 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.012 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
Revenue analysis

0.012 B 100%
0.0067 B 57%
-0.011 B -94%
-0.012 B -97%

Balance Sheet

0.088 B
0.023 B

0.051 B

Financial Position Analysis

Assets

0.088 B
Current Assets
0.041 B
Total non-current assets
0.047 B

Total current liabilities
0.057 B
Total non-current liabilities
0.0079 B

Cash Flow Statement

-0.0092 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.008 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A

Avacta Group PLC fundamental analysis for trailing twelve months (TTM)

Profitability Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Solvency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Efficiency Indicators

-208 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%
-55 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%
-47 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Dupont Analysis

Stability Indicators

STOCK ANALYSIS

Is AVCT attractive for investment based on fundamental analysis?

AVCT stock rating is hidden. Avacta Group PLC is a hidden by Eyestock methodology.

Get AVCT Stock Rating
to complete you analysis
UNLOCK
Learn more about quality score?

Net Profit Margin:

-267

Gross Margin:

54

CFO / Debt ratio:

hidden

Current ratio:

0.772

Debt / Equity ratio:

2.765

ROE:

-208

ROIC:

hidden

Stability Ratio (2y):

hidden

Stability Ratio (5y):

hidden

Earnings quality:

hidden

AVCT.L analysis by AI

Eyebot AI analysis

We carefully consider 10 indicators for AVCT.L to calculate the final rating score. Use AI leverage to quickly get the main conclusions before diving into the details

Avacta Group PLC competitors

AB

ABBV

Abbvie Inc

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Ill...

Discover

AM

AMGN

Amgen Inc

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. The Company...

Discover

VR

VRTX

Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs fo...

Discover

Avacta Group PLC dividends

AVCT.L dividend metrics

Payout ratio
Dividend yield
Annual dividend
Dividend streak
Average dividend yield over 3 years
Average dividend yield over 5 years

Dividend per share

By years
By payments
1y
3y
5y
All time
This ticker has no dividend history

About AVCT.L stock

About the company Avacta Group PLC

Market cap $B

0.34

Dividend yield

Shares outstanding

265.84 B

Avacta Group Plc engages in the provision of Affimer reagents for licensing into third-party research and diagnostic products, and creates new Affimer medicines for development in-house and licensing to large pharmaceutical companies. The company is headquartered in Wetherby, West Yorkshire and currently employs 133 full-time employees. The company went IPO on 2003-09-08. The firm is focused on developing cancer immunotherapies and diagnostics based on its Affimer and prelCISION platforms. The company has two divisions: Therapeutics and Diagnostics. Avacta’s therapeutics division develops cancer immunotherapies combining its platforms: Affimer biotherapeutics and prelCISION tumor targeted chemotherapy. The Affimer platform is a class of biotherapeutic based on a naturally occurring human protein. Avacta's prelCISION targeted chemotherapy platform releases active chemotherapy in the tumor, which limits the systemic exposure that causes damage to healthy tissues, and thereby improves the overall safety and therapeutic potential of these anti-cancer treatments. The Company’s diagnostics division utilizes its Affimer platform to develop diagnostics and works with partners world-wide to develop Affimer reagents with the objective of establishing royalty-bearing license deals.

AVCT.L profile

  • Ticker

    AVCT.L

  • Country

    Great Britain

  • Exchange

    XLON - London Stock Exchange

  • Report currency

    GBP - British pound

  • IPO date

    08 September 2003

  • Sector

    Healthсare

  • Industry

    Biotechnology

  • Employees

    133

  • City

    Wetherby

  • Address

    Unit 20, Ash Way

  • Cusip

    G2967N117